AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
88_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
25_CD
Disposal_NN
of_PIN
business_NOMZ
operations_NOMZ
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
70_CD
Current_JJ
assets_NN
34_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
17_CD
Book_NN
value_NN
of_PIN
net_JJ
assets_NN
disposed_VBD
87_CD
Less_RB
:_:
Cash_NN
included_VBD
in_PIN
undertakings_GER
disposed_VBD
7_CD
Cash_NN
consideration_NOMZ
80_CD
The_DT
sale_NN
consideration_NOMZ
received_VBN [WZPAST]
is_VPRT [BEMA]
in_PIN
relation_NOMZ
to_PIN
the_DT
sale_NN
of_PIN
Marlow_NN
Foods_NN
Limited_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
completed_VBN
on_PIN
23_CD
May_POMD
2003_CD
._.
Marlow_NN
Foods_NN
Limited_NN
results_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
for_PIN
the_DT
period_NN
up_IN
to_PIN
disposal_NN
._.
Prior_RB
to_PIN
its_PIT
disposal_NN
,_,
Marlow_NN
Foods_NN
Limited_NN
contributed_VBD
$_$
6m_CD
to_TO
operating_VBG
cash_NN
flows_NN
and_CC
absorbed_VBN
$_$
1m_CD
in_PIN
respect_NN
of_PIN
fixed_JJ
capital_NN
expenditure_NN
._.
There_EX
was_VBD
no_SYNE
gain_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
26_CD
Reconciliation_NOMZ
of_PIN
net_JJ
cash_NN
flow_NN
to_PIN
movement_NOMZ
in_PIN
net_JJ
funds_NN
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Decrease_NN
in_PIN
cash_NN
4_CD
22_CD
396_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
decrease_NN
increase_NN
in_PIN
loans_NN
and_CC
short_JJ
term_NN
borrowings_GER
345_CD
118_CD
35_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
increase_NN
decrease_NN
in_PIN
short_JJ
term_NN
investments_NOMZ
771 806 260_CD
Change_NN
in_PIN
net_JJ
funds_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
430 902 691_CD
Exchange_NN
movements_NOMZ
82_CD
75_CD
47_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
348 977 738_CD
Net_JJ
funds_NN
at_PIN
1_CD
January_NN
3,844_CD
2,867_CD
3,605_CD
Net_JJ
funds_NN
at_PIN
31_CD
December_NN
3,496_CD
3,844_CD
2,867_CD
